Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study - sprookjes - yvandenbroek - TriplyDB

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

http://www.wikidata.org/entity/Q37527438

about

Bringing patient centricity to diabetes medication access in Canada Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.Cardiovascular safety of therapies for type 2 diabetes.An update on DPP-4 inhibitors in the management of type 2 diabetes.Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries.Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment.Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.Anti-diabetic agents and heart health: how to use new diabetes medications in a global strategy for the prevention of cardiovascular complications in type 2 diabetes.

P2860

Q28067085-D5305A05-EF13-4320-998F-B5CD4B00C7BE Q37101613-E0C8899E-6A15-4BD7-8DDB-87B66F25F0BF Q37384190-055E61B2-B1CE-48FB-8357-9D5FC43F8EAB Q37620904-9D60C8CE-F752-4AD7-9E3E-DC0B7258F0D1 Q37722896-372C79DB-0B9D-4766-B402-D09E25A5D168 Q38825446-8CB982F7-F685-4387-B2D3-643F53CCF5A9 Q38907817-1ED0F93E-EFB3-4F42-848B-0DC83A132E76 Q38955525-2299CAFA-CF58-4016-8053-825EEF2072B5 Q38960547-183529EE-BA09-4B10-ACA7-F4755C0C3CF2 Q38997456-D78D1034-71AC-460A-822A-FDFCD4D81D30 Q39164190-4AED80BA-95BE-4C00-BEE1-6834AD44D31C Q41107105-83CCE76B-4B7F-4537-B3B7-4865E4622967 Q41176211-EEE49916-340A-4094-9A1E-0B39F4724F00 Q47225473-2472717E-36F9-45B1-B0C8-A529A7AD2715 Q47369849-5E5F3430-1395-4624-937D-249F80EA89FC Q47687852-8BBCF5E3-97C2-4869-BCFF-3BAB51FC1D5A Q48274537-DFFE0B1A-C2BF-4209-948A-7077631E78C3 Q52603694-C6F6D275-7BBF-4819-BBC3-2DCE9C1A55C8 Q54993721-89C64F82-3C46-46E8-B1B2-F086E9F6DFCC Q55315711-52C47E75-71AF-4D47-83C4-5384C88D8016

P2860

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

http://www.wikidata.org/entity/Q37527438

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Risk for Hospitalized Heart Fa ...... : A Retrospective Cohort Study

@en

Risk for Hospitalized Heart Fa ...... A Retrospective Cohort Study.

@nl

type

label

Risk for Hospitalized Heart Fa ...... : A Retrospective Cohort Study

@en

Risk for Hospitalized Heart Fa ...... A Retrospective Cohort Study.

@nl

prefLabel

Risk for Hospitalized Heart Fa ...... : A Retrospective Cohort Study

@en

Risk for Hospitalized Heart Fa ...... A Retrospective Cohort Study.

@nl

P1433

Q37527438-08C8848F-9A83-4483-9C42-AA2CB77E0FFD

P1476

Q37527438-3C48128F-A44C-4D21-A451-F30073235982

P2093

Q37527438-1A74AA0B-4A1A-4379-BEE1-BDBBD567E6AF

Q37527438-1C1879B3-7A3B-40E0-9AFE-E8D21F78DF2F

Q37527438-1EA145C3-CD9C-46F7-A516-0E5B0404BE2F

Q37527438-413866E2-01ED-47C8-99B3-16A82D51EC5E

Q37527438-6080B4BA-6183-4AEC-B58A-BAC596A6D711

Q37527438-6665DEC2-1F67-4855-A1B0-3D4828EEDEF9

Q37527438-6C4EA501-B346-4A6B-9A67-73AB06139CBE

Q37527438-74327876-E96F-48ED-9DD9-5955E31A677E

Q37527438-91E5E2FD-E060-461D-A969-37189D7B596D

Q37527438-D5103E8E-B244-416C-AC13-47C2B17C18D0

P2860

Q37527438-06125146-A505-490A-96CA-64D80C486D55

Q37527438-0C7DADAB-F09D-4506-BBAF-C99F3BAF5D5E

Q37527438-21078926-5229-48FB-9ED8-561AC5465C3A

Q37527438-21F9ED9A-C5B3-4241-B3F9-C38FB3D890A2

Q37527438-2739ED60-9871-4965-91FF-F86E3345C8A4

Q37527438-2962E8F8-3A95-40B3-8157-C12598AF77D8

Q37527438-31BDBE36-2263-4764-B775-C65BC76CC00C

Q37527438-38E9F351-61BE-46F5-BB6D-22BB03ED9595

Q37527438-3B906795-6A09-4AEA-BC17-9EF6A171905D

Q37527438-40C26A07-A29E-436A-8510-36E2D286F429

P304

Q37527438-9997C8F5-1E92-412C-A441-D72B28E8D500

P31

Q37527438-AF92BE16-376A-426F-BB2D-E377DBE43DF7

P356

Q37527438-3B38A167-02B2-45BC-B959-69EE484765B1

P407

Q37527438-C09D7CD3-5E09-4EFA-BF4B-19AAAEBFDC17

P433

Q37527438-CA40B128-D27B-4557-BB6E-C1A1E9F3EE35

P478

Q37527438-17DDEA57-B8AB-478A-B7B1-5B31DBCE0E35

P50

Q37527438-260A6880-C4FE-45AE-A079-A62373CC1FA3

Q37527438-B1CC623C-B2E2-4F3D-A68A-43891EB759E6

P577

Q37527438-781948F4-A3AC-4E5B-A143-A8D47DF8A3CA

P698

Q37527438-A96B570B-2194-4493-A2FD-D5074D16F1D9

P921

Q37527438-47D5D719-321C-4F12-9BB7-2112E4D69CB2

Q37527438-C7AA42F7-1A2F-427A-AB62-ACC73B7EF10E

P932

Q37527438-16E5B434-A099-4DD7-A782-81ABAFA6DF95

P356

P1433

Annals of Internal Medicine

P1476

Risk for Hospitalized Heart Fa ...... : A Retrospective Cohort Study

@en

P2093

Aarthi Iyer

http://www.w3.org/2001/XMLSchema#string

Bruce H Fireman

http://www.w3.org/2001/XMLSchema#string

Christian Hampp

http://www.w3.org/2001/XMLSchema#string

David J Graham

http://www.w3.org/2001/XMLSchema#string

Frank Pucino

http://www.w3.org/2001/XMLSchema#string

Madelyn Pimentel

http://www.w3.org/2001/XMLSchema#string

Malcolm Rucker

http://www.w3.org/2001/XMLSchema#string

Marie R Griffin

http://www.w3.org/2001/XMLSchema#string

Marsha E Reichman

http://www.w3.org/2001/XMLSchema#string

Nancy J Brown

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of validated methods for identifying heart failure using administrative data

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Mini-Sentinel and regulatory science--big data rendered fit and functional.

A basic study design for expedited safety signal evaluation based on electronic healthcare data.

A policy framework for public health uses of electronic health data.

Design considerations, architecture, and use of the Mini-Sentinel distributed data system.

A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

P304

705-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/M15-2568

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27110660

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

5178978

http://www.w3.org/2001/XMLSchema#string